AI analytics company raises $10M

CLEW, a Netanya, Israel-based healthcare technology company, announced that it has raised $10 million in Series B funding.

The funds are expected to go toward commercializing CLEW’s AI analytics platform in the tele-ICU and critical care markets. The platform was designed to improve clinical outcomes and cut costs by helping providers predict life-threatening complications in advance.

“We view this round of funding as further validation of our technology and product offering,” CLEW CEO Gal Salomon said in a prepared statement.

Pitango Venture Capital led the funding round, with all of the company’s previous investors also contributing. Relyens, a healthcare-focused mutual group insurance and risk manager, also provided “additional strategic participation.”

“CLEW has clearly demonstrated the value that AI can bring to critical care” Ittai Harel, managing general partner at Pitango Venture Capital, said in the same statement. “We are pleased to have led this round of funding and look forward working with CLEW as they expand their footprint in the U.S.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.